

Peter Carroll

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12092724/publications.pdf>

Version: 2024-02-01

22
papers

2,042
citations

623734

14
h-index

610901

24
g-index

27
all docs

27
docs citations

27
times ranked

3407
citing authors

#	ARTICLE	IF	CITATIONS
1	Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. <i>European Urology Open Science</i> , 2022, 35, 59-67.	0.4	13
2	Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: An analysis of the G.A.P.3 global consortium database. <i>Prostate</i> , 2022, 82, 876-879.	2.3	2
3	Personalised biopsy schedules based on risk of Gleason upgrading for patients with low-risk prostate cancer on active surveillance. <i>BJU International</i> , 2021, 127, 96-107.	2.5	15
4	Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance Initiative. <i>European Urology Oncology</i> , 2020, 3, 80-91.	5.4	24
5	Development of Treatments for Localized Prostate Cancer in Patients Eligible for Active Surveillance: U.S. Food and Drug Administration Oncology Center of Excellence Public Workshop. <i>Journal of Urology</i> , 2020, 203, 115-119.	0.4	9
6	Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts. <i>European Urology</i> , 2019, 76, 693-702.	1.9	18
7	Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium. <i>European Urology</i> , 2019, 75, 523-531.	1.9	58
8	A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen ≥ 10 ng/ml at Initial Biopsy. <i>European Urology</i> , 2018, 74, 731-738.	1.9	186
9	Report of the Second Asian Prostate Cancer (A-CaP) Study Meeting. <i>Prostate International</i> , 2017, 5, 95-103.	2.3	7
10	A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy. <i>JAMA Oncology</i> , 2016, 2, 882.	7.1	458
11	An Approach Using PSA Levels of 1.5 ng/mL as the Cutoff for Prostate Cancer Screening in Primary Care. <i>Urology</i> , 2016, 96, 116-120.	1.0	11
12	Asia prostate cancer study (A-CaP Study) launch symposium. <i>Prostate International</i> , 2016, 4, 88-96.	2.3	7
13	Overdiagnosis and Overtreatment of Prostate Cancer. <i>European Urology</i> , 2014, 65, 1046-1055.	1.9	709
14	Seventh Joint Meeting of K-J-CaP and CaPSURE: extending the global initiative to improve prostate cancer management. <i>Prostate International</i> , 2014, 2, 50-69.	2.3	4
15	A Group of Genome-Based Biomarkers That Add to a Kattan Nomogram for Predicting Progression in Men with High-Risk Prostate Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 195-202.	7.0	34
16	High-Resolution Analysis of Paraffin-Embedded and Formalin-Fixed Prostate Tumors Using Comparative Genomic Hybridization to Genomic Microarrays. <i>American Journal of Pathology</i> , 2003, 162, 763-770.	3.8	76
17	CpG hypermethylation of promoter region and inactivation of E-cadherin gene in human bladder cancer. <i>Molecular Carcinogenesis</i> , 2002, 34, 187-198.	2.7	76
18	METHYLATION OF THE E-CADHERIN GENE PROMOTER CORRELATES WITH PROGRESSION OF PROSTATE CANCER. <i>Journal of Urology</i> , 2001, 166, 705-709.	0.4	116

#	ARTICLE	IF	CITATIONS
19	FREQUENTLY DELETED LOCI ON CHROMOSOME 9 MAY HARBOR SEVERAL TUMOR SUPPRESSOR GENES IN HUMAN RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 2001, 166, 1088-1092.	0.4	32
20	Frequent homozygous deletion of cyclin-dependent kinase inhibitor 2 (MTS1, p16) in superficial bladder cancer detected by fluorescence in situ hybridization. <i>Genes Chromosomes and Cancer</i> , 1997, 19, 84-89.	2.8	49
21	Deletion of chromosome 11p15, p12, q22, q23-24 loci in human prostate cancer. , 1997, 72, 283-288.		46
22	Chromosome-9 loss detected by fluorescence in situ hybridization in bladder cancer. <i>International Journal of Cancer</i> , 1995, 64, 99-103.	5.1	61